Therapy News and Research

RSS

Innovative treatments can lead to functional improvements in patients with SCIs

A series of rehabilitation studies published in the September 2012 issue of the Archives of Physical Medicine & Rehabilitation demonstrate that innovative treatments for individuals with spinal cord injuries can lead to significant functional improvements in patients and a higher quality of life.

9 Oct 2012

New data from Genzyme's AUBAGIO and LEMTRADA clinical trials to be presented at ECTRIMS

Genzyme, a Sanofi company, announced today new data from Genzyme's clinical development programs for AUBAGIO (teriflunomide) and LEMTRADATM (alemtuzumab) will be presented at the 28th Congress of the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS) in Lyon, France, October 10-13.

9 Oct 2012

Study examines trends in HIV mortality

Overall death rates due to human immunodeficiency virus (HIV) infection declined over time between 1993 and 2007 for most men and women by race/ethnicity and educational levels, with the largest absolute decreases for nonwhites, but rates remain high among blacks, according to a report published Online First by Archives of Internal Medicine, a JAMA Network publication.

9 Oct 2012

New blood test can read genetic changes in prostate cancer

Scientists have designed a blood test that reads genetic changes like a barcode - and can pick out aggressive prostate cancers by their particular pattern of gene activity.

9 Oct 2012

HPV status predicts oropharyngeal cancer irradiation response

Human papillomavirus-positive head and neck cancer is more sensitive to the initial effects of radiation therapy than HPV-negative head and neck cancer, suggest study findings.

8 Oct 2012

NCI awards Cellerant SBIR contract to develop Megakaryocyte Progenitor Cell therapy for thrombocytopenia

Cellerant Therapeutics Inc., a biotechnology company developing novel hematopoietic stem cell-based cellular and antibody therapies for blood disorders and cancer, announced today that it has been awarded a Small Business Innovation Research (SBIR) Phase 1 contract and a Phase 2 option from the National Cancer Institute (NCI) valued up to $1,683,503.

8 Oct 2012

Trevena reports completion of TRV027 Phase 2a study in advanced heart failure patients

Trevena, Inc., the leader in the discovery and development of G-protein coupled receptor (GPCR) biased ligands, today announced that it has successfully completed a Phase 2a study on the hemodynamic effects of TRV027 in patients with advanced heart failure with reduced ejection fraction.

8 Oct 2012

Positive results from Cempra's IV solithromycin Phase 1 study

Cempra, Inc., a clinical-stage pharmaceutical company focused on developing antibiotics to meet critical medical needs in the treatment of bacterial infectious diseases, today announced results of its Phase 1 study of intravenous (IV) solithromycin in healthy subjects. The study demonstrated that IV solithromycin was well tolerated, showed a favorable pharmacokinetic profile (PK) and achieved relevant plasma concentrations.

8 Oct 2012

St. Jude Medical launches 3-D navigation system that reduces need for live fluoroscopy

St. Jude Medical, Inc., a global medical device company, today announced the launch of its MediGuide Technology, the first and only three-dimensional (3-D) navigation system intended for the evaluation of vascular and cardiac anatomy on a recorded fluoroscopic image instead of live fluoroscopy (a series of X-ray images).

8 Oct 2012

Hygieia granted CE mark for d-Nav Diabetes Insulin Guidance System

Hygieia, Inc. today announced that the company's d-Nav Diabetes Insulin Guidance System (DIGS) has been granted a CE mark.

8 Oct 2012

FCP reports launch of comprehensive pharmacy services company, AlixaRx

Fillmore Capital Partners, a private investment company, today announced the formal launch of AlixaRx, a company that has been in development over the past four years. AlixaRx will provide comprehensive pharmacy services to post-acute and numerous other healthcare settings.

8 Oct 2012

Functional profiling using EVA/PCD doubles response rate and improves survival in NSCLC patients

Functional profiling using ex-vivo analysis of programmed cell death (EVA/PCD) doubles the response rate and improves time-to-progression and survival in patients with advanced lung cancer, according to a Phase II clinical trial conducted by investigators at Rational Therapeutics and the MemorialCare Todd Cancer Institute and published in the October issue of Anticancer Research.

8 Oct 2012

Patient navigation services can reduce dangerous delays in identification of breast cancer

Today researchers from The George Washington University published a study showing that breast cancer patients can reduce potentially dangerous delays in the identification of breast cancer with the assistance of patient navigation services.

8 Oct 2012

Parametric response mapping could improve diagnosis and treatment of COPD

A new approach to lung scanning could improve the diagnosis and treatment of a lung disease that affects approximately 24 million Americans and is the country's third-highest cause of death.

8 Oct 2012

Researchers decipher how AP-1 gene regulator controls survival of liver tumor-initiating cells

Researchers headed by Erwin Wagner, the Director of the BBVA Foundation-CNIO Cancer Cell Biology Programme at the Spanish National Cancer Research Centre (CNIO), have deciphered how a stress-inducible gene regulator, AP-1, controls the survival of liver tumor-initiating cells. These results, published in the online edition of Nature Cell Biology, could provide new preventive strategies and identify potentially targetable molecules to prevent liver cancer.

8 Oct 2012

FDA clears Fenwal's new plasma products

Fenwal Inc., a global leader specializing in separation technologies for blood and cell collection and therapy, announced today it has received clearance from the U.S. Food and Drug Administration for two new indications for collection of plasma products on the Fenwal Alyx and Amicus systems.

8 Oct 2012

Therapy News and Research

Innovative treatments can lead to functional improvements in patients with SCIs

New data from Genzyme's AUBAGIO and LEMTRADA clinical trials to be presented at ECTRIMS

Study examines trends in HIV mortality

New blood test can read genetic changes in prostate cancer

HPV status predicts oropharyngeal cancer irradiation response

NCI awards Cellerant SBIR contract to develop Megakaryocyte Progenitor Cell therapy for thrombocytopenia

Trevena reports completion of TRV027 Phase 2a study in advanced heart failure patients

Positive results from Cempra's IV solithromycin Phase 1 study

St. Jude Medical launches 3-D navigation system that reduces need for live fluoroscopy

Hygieia granted CE mark for d-Nav Diabetes Insulin Guidance System

FCP reports launch of comprehensive pharmacy services company, AlixaRx

Functional profiling using EVA/PCD doubles response rate and improves survival in NSCLC patients

Patient navigation services can reduce dangerous delays in identification of breast cancer

Parametric response mapping could improve diagnosis and treatment of COPD

Researchers decipher how AP-1 gene regulator controls survival of liver tumor-initiating cells

FDA clears Fenwal's new plasma products

Translational Genomics Research Institute creates new center for rare childhood disorders

NIH awards $2.1M grant to study possible ways to fight cancer

Nelfinavir inhibits growth of HER2-positive tumors

91 charged with $430 million Medicare billing fraud

The Critical Role of Sample Storage in Drug Discovery and Development

Advancing Neuroscience Research Through Collaboration and Patient-Centered Innovation

The impact of vibration on microscopy

Latest News